argenx SE (NASDAQ:ARGX) Stock Position Lifted by Bank of Montreal Can

Bank of Montreal Can raised its position in shares of argenx SE (NASDAQ:ARGX) by 9.4% in the third quarter, HoldingsChannel.com reports. The firm owned 8,307 shares of the company’s stock after buying an additional 714 shares during the period. Bank of Montreal Can’s holdings in argenx were worth $4,453,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Clearbridge Investments LLC lifted its position in shares of argenx by 3.6% in the 2nd quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock valued at $265,535,000 after acquiring an additional 21,189 shares in the last quarter. Sei Investments Co. boosted its stake in shares of argenx by 15.2% during the 2nd quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after acquiring an additional 50,477 shares in the last quarter. Jennison Associates LLC grew its holdings in argenx by 0.6% during the third quarter. Jennison Associates LLC now owns 237,966 shares of the company’s stock valued at $128,997,000 after purchasing an additional 1,528 shares during the last quarter. Fiera Capital Corp grew its position in shares of argenx by 2.2% in the second quarter. Fiera Capital Corp now owns 165,595 shares of the company’s stock valued at $71,212,000 after purchasing an additional 3,506 shares during the last quarter. Finally, Perpetual Ltd bought a new stake in shares of argenx in the third quarter valued at approximately $76,314,000. Institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ARGX. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research report on Tuesday, November 12th. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Barclays upgraded shares of argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Wedbush reissued an “outperform” rating and set a $655.00 target price on shares of argenx in a research note on Tuesday. Finally, Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and boosted their price target for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and a consensus target price of $635.42.

argenx Trading Down 1.8 %

Shares of ARGX stock opened at $606.47 on Wednesday. argenx SE has a 12 month low of $327.73 and a 12 month high of $622.32. The firm has a market capitalization of $36.61 billion, a PE ratio of -689.17 and a beta of 0.59. The firm has a fifty day simple moving average of $567.51 and a two-hundred day simple moving average of $499.76.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter last year, the firm earned ($1.25) EPS. On average, equities analysts predict that argenx SE will post 2.2 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.